GlassScriptPhysician profile
Frank S Virant
NPI 1275569766
$107,170.06
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41K · 2020: $20K · 2021: $30K · 2022: $14K · 2023: $995 · 2024: $226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,221.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,221.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $36,970.15 | 2019-2024 | Fasenra, Brilinta, Tezspire |
| Glaxosmithkline, LLC. | $33,860.95 | 2019-2024 | Trelegy Ellipta, Nucala, Arexvy |
| Regeneron Healthcare Solutions, INC. | $10,030.57 | 2019-2021 | |
| Leo Pharma INC. | $8,124.68 | 2020-2022 | |
| Genzyme Corporation | $6,293.80 | 2019-2024 | |
| Alk-Abello, INC | $4,236.39 | 2019-2023 | Ragwitek, Grastek, Odactra |
| Regeneron Pharmaceuticals, INC. | $3,450.00 | 2021 | |
| Genentech USA, INC. | $1,557.71 | 2022-2023 | Xolair |
| Blueprint Medicines Corporation | $1,508.00 | 2020-2023 | Ayvakit |
| Pfizer INC. | $281.44 | 2023-2024 | |
| Biocryst US Sales Co., LLC | $175.46 | 2023-2024 | Orladeyo |
| Novartis Pharmaceuticals Corporation | $152.26 | 2019-2023 | |
| Kaleo, INC. | $84.39 | 2021-2022 | |
| Genentech, INC. | $82.80 | 2022 | |
| Abbvie INC. | $80.41 | 2022-2023 | Rinvoq |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $57.02 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.93 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $48.98 | 2020-2023 | Cuvitru |
| Csl Behring | $43.27 | 2019-2021 | |
| Shire North American Group INC | $36.19 | 2019 | |
| Optinose US, INC. | $21.37 | 2021 | |
| Sanofi-Aventis U.S. LLC | $18.29 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Virant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.